

LIST OF TABLES

		Page
Table I	Number of patients whose data were used for analyses in different chapters of Report No. 13	10
Table II	Distribution of prognostic stages in patients diagnosed in 2018	10
Table 1.1	Body mass index at diagnosis (N=20,868)	22
Table 1.2	Family history of breast cancer at diagnosis (N=20,868)	23
Table 1.3	Personal history of other tumours at diagnosis (N=20,868)	23
Table 1.4	Origins of malignant tumours reported by patients (N=376)	24
Table 1.5	History of benign breast disease at diagnosis (N=20,868)	25
Table 1.6	Menarche, menopause and reproductive history at diagnosis	26
Table 1.7	Number of live births reported by patients (N=15,688)	26
Table 1.8	Use of hormonal contraceptives at diagnosis (N=20,868)	27
Table 1.9	Use of hormone replacement therapy at diagnosis (N=11,108)	28
Table 1.10	Ten most common risk factors for breast cancer in patient cohort (N=20,868)	28
Table 1.11	Breast screening habits by age group (N=20,612)	30
Table 1.12	Breast screening habits by education level (N=20,701)	31
Table 1.13	Breast screening habits by monthly household income (HK\$) (N=11,433)	32
Table 1.14	Breast screening habits by district of residence (N=19,981)	33
Table 2.1	Methods of first breast cancer detection by type of medical service users (N=19,062)	39
Table 2.2	Methods of first breast cancer detection by type of cancer (N=18,922)	40
Table 2.3	Methods of first breast cancer detection by cancer stage (N=18,298)	40
Table 2.4	Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer (N=4,255)	41
Table 2.5	Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer by type of medical service users (N=4,255)	42
Table 2.6	Cancer stage at diagnosis among self-detected patients by time interval between onset of symptoms and first medical consultation (N=3,734)	42
Table 2.7	Number of patients and breast cancer cases in the patient cohorts (N=20,138)	43
Table 2.8	Sensitivity and diagnostic results of breast imaging tests (N=20,138)	45
Table 2.9	Mammographic findings of patients diagnosed through mammography (N=14,582)	46
Table 2.10	Mammographic density of breasts of patients diagnosed through mammogram by age group (N=9,864)	47
Table 2.11	Sensitivity and diagnostic results of breast tissue biopsies (N=20,138)	48
Table 2.12	Method of cancer staging among invasive breast cancer patients (N=8,020)	49



		Page
Table 2.13	Use of PET scan among patients who had cancer staging by cancer stage (N=8,020)	49
Table 2.14	Histological type of invasive breast cancer (N=16,996)	53
Table 2.15	Grading, multifocality and multicentricity of invasive breast cancer (N=16,996)	54
Table 2.16	Biological characteristics of invasive breast cancer (N=16,996)	55
Table 2.17	Biological subtypes of invasive tumours by cancer stage (N=15,853)	56
Table 2.18	Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=2,617)	57
Table 2.19	Biological characteristics of in situ breast cancer (N=2,617)	58
Table 2.20	Use of surgery for patients with invasive cancer	60
Table 2.21	Use of surgery for patients with in situ cancer	61
Table 2.22	Type of breast surgery by age group (N=19,320)	62
Table 2.23	Type of breast surgery by invasive tumour size (cm) (N=15,405)	62
Table 2.24	Type of breast surgery by cancer stage (N=19,044)	62
Table 2.25	Type of breast surgery by type of medical service (N=18,937)	63
Table 2.26	Type of nodal surgery by clinical nodal status (N=18,388)	63
Table 2.27	Type of nodal surgery for invasive cancer by cancer stage (N=16,194)	64
Table 2.28	Distribution of tumour size (cm) in invasive cancer with negative or positive nodal status (N=14,231)	64
Table 2.29	Number of positive nodes by type of nodal surgery (N=17,911)	65
Table 2.30	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=7,355)	67
Table 2.31	Chemotherapy treatment by cancer stage (N=16,713)	68
Table 2.32	Use of chemotherapy by age group and cancer stage at diagnosis (N=16,418)	68
Table 2.33	Forms of endocrine therapy by age group (N=12,422)	82
Table 2.34	Type of targeted therapy drugs used (N=2,795)	82
Table 2.35	Number of treatment modalities by cancer stage (N=19,309)	83
Table 2.36	Follow-up of patients (N=18,155)	85
Table 2.37	Locoregional recurrence by type of surgery received and cancer stage at diagnosis	86
Table 2.38	Sites involved in locoregional recurrence (N=627)	86
Table 2.39	Organs involved in distant recurrence (N=750)	86
Table 2.40	Time for organ specific metastasis and distribution of the biological subtypes of patients	87
Table 2.41	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=15,950)	87
Table 2.42	Characteristics of breast cancer-specific deaths (N=232)	88
Table 3.1	Mean scores on cancer-specific scale	94
Table 3.2	Psychosocial impact of breast cancer	97



LIST OF FIGURES

		Page
Figure I	Distribution of year of diagnosis of HKBCR participants	6
Figure 1.1	Distribution of age at diagnosis (N=20,868)	15
Figure 1.2	Occupation of patient cohorts (N=20,868)	16
Figure 1.3	Education level of patient cohorts (N=20,868)	17
Figure 1.4	Monthly household income (HK\$) of patient cohorts (N=11,433)	17
Figure 1.5	District of residence of patient cohorts (N=20,868)	18
Figure 1.6	Bra band size of patient cohorts (N=20,868)	19
Figure 1.7	Bra cup size of patient cohorts (N=20,868)	19
Figure 1.8	Dietary habits at diagnosis (N=20,868)	21
Figure 1.9	Exercise habits at diagnosis (N=20,868)	21
Figure 1.10	Stress level at diagnosis (N=20,868)	21
Figure 1.11	Distribution of risk factors among patients at diagnosis (N=20,868)	29
Figure 2.1	Methods of first breast cancer detection in the patient cohorts (N=19,062)	39
Figure 2.2	Major presenting symptoms of self-detected breast cancer in the patient cohorts (N=15,692)	41
Figure 2.3	Locations of malignant tumour on breasts within the patient cohorts (N=20,138)	44
Figure 2.4	Mammographic density of breasts of patients diagnosed through mammogram (N=10,037)	46
Figure 2.5	Cancer stage at diagnosis (N=20,138)	50
Figure 2.6	Distribution of tumour size (cm) of invasive breast cancer (N=14,561)	51
Figure 2.7	Number of positive axillary lymph nodes among patients with invasive breast cancer (N=16,134)	52
Figure 2.8	Distribution of tumour size (cm) of in situ breast cancer (N=2,159)	52
Figure 2.9	Use of locoregional radiotherapy among patients who underwent breast-conserving surgery by cancer stage (N=7,087)	66
Figure 2.10	Use of locoregional radiotherapy among patients who underwent mastectomy by cancer stage (N=11,634)	66
Figure 2.11	Type of first generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=162)	69
Figure 2.12	Type of second generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=145)	69
Figure 2.13	Type of third generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=521)	70
Figure 2.14	Type of HER2 regimens used in neoadjuvant setting (N=437)	70
Figure 2.15	Type of chemotherapy regimens used by biological subtype in neoadjuvant setting (N=1,208)	71
Figure 2.16	Type of first generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=1,671)	73
Figure 2.17	Type of second generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,616)	73



		Page
Figure 2.18	Type of third generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,718)	74
Figure 2.19	Type of HER2 regimens used in adjuvant setting (N=825)	74
Figure 2.20	Type of chemotherapy regimens used by biological subtype in adjuvant setting (N=8,269)	75
Figure 2.21	Type of chemotherapy regimens used by cancer stage in adjuvant setting (N=8,418)	77
Figure 2.22	Type of chemotherapy regimens used by biological subtype in palliative setting (N=283)	78
Figure 2.23	Use of endocrine therapy by cancer stage (N=19,309)	81
Figure 2.24	Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=3,480)	83
Figure 2.25	Type of complementary and alternative therapies used (N=7,201)	84
Figure 3.1	Level of physical discomfort after surgery (N=17,829)	91
Figure 3.2	Level of physical discomfort after radiotherapy (N=10,490)	91
Figure 3.3	Level of physical discomfort after chemotherapy (N=9,149)	92
Figure 3.4	Level of physical discomfort after endocrine therapy (N=11,300)	92
Figure 3.5	Level of physical discomfort after targeted therapy (N=2,303)	93
Figure 3.6	Correlations between symptom scales and age	95
Figure 3.7	Correlations between functional scales and age	95
Figure 3.8	Correlations between emotional scales and age	98